AAL

Oncology Stock Pops on Promising Drug Data

The stock is headed for its third straight daily win

Digital Content Manager
Jun 14, 2019 at 9:42 AM
facebook X logo linkedin


Drugmaker Kura Oncology Inc (NASDAQ:KURA) just announced that its ongoing Phase 2 clinical trial for its experimental lymphoma drug, tipifarnib, met its primary endpoint today. The cancer researcher said the treatment's results yielded "ongoing anti-tumor activity and a manageable safety profile." KURA shares are higher in response, up 3.6% at $219.19 pacing for their best day since September 2017. 

What's more, the stock is pacing for not only its third straight daily win, but its second week in the black, as well. At yesterday's close, the equity had already tacked on 81% since it's late-October low of $10.20, with recent support from the 30-day moving average.

Analysts have been hip to KURA, with all eight in coverage giving the oncology concern a "buy" or better rating. Plus, the consensus 12-month target price of $27.71 represents a region the stock has yet to cross.

Short interest has been telling a different story, however. These bearish bets shot up 6.5% in the last reporting period. Currently, the 2.1 million shares sold short represents a healthy 7% of the stock's available float. Plus, it would take over two weeks to buy back all these pessimistic positions at the security's average pace of trading. Should some of these bearish bets begin to unwind, a short squeeze could help propel KURA even higher.  

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.